Iconocast Logo

Welcome To Iconocast

blank

Recent News on the Keywords, aspirin use + breast cancer + aspirin , Related to the Article Below:


San Diego Union Tribune
In new book, KC Nicolaou celebrates our better history through ...
San Diego Union Tribune, United States - Apr 24, 2008
They range from the familiar ? aspirin and steroids ? to the strange and unpronounceable, such as brevetoxin B (a marine neurotoxin associated with red ...
The pain of Roshanara
InfoChange, India - Apr 9, 2008
In the 1970s, the medical community had to think beyond aspirin. Patients in excruciating pain were given pure opium dissolved in tea. ...
New data will help guide prescribing of celecoxib
TheHeart.Org, NY - Mar 31, 2008
Celecoxib was associated with increased risk regardless of baseline aspirin use, and there was no differential effect based on any prespecified subgroups. a ...
Let's Stop Running Scared
New America Foundation, DC - Mar 31, 2008
Every drug you can name, from aspirin to Zocor, has side effects -- some potentially more serious than the diseases they are supposed to prevent. ...
Source: Google News
 

Aspirin Use Associated With Reduced Risk of Breast Cancer

May 28, 2004 — Women who report regular use of aspirin appear to have a reduced risk of breast cancer, according to a study in the May 26 issue of The Journal of the American Medical Association.

While cancer epidemiology and prevention have traditionally focused on the identification and modification of lifestyle factors that may increase or decrease the risk of various cancers, much recent attention has been centered on chemoprevention, the use of chemical agents to prevent or inhibit the carcinogenic process, according to background information in the article. Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. Given the importance of estrogen in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status.

Mary Beth Terry, Ph.D., of Columbia University, New York, and colleagues conducted a study to determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and whether any observed association is more pronounced for women with hormone receptor-positive breast cancers. The study, which included in-person interviews, was conducted during 1996-1997. There were 1,442 breast cancer cases and 1,420 controls.

Article continues below and (thank you)

 
The researchers found that ever use of aspirin or other NSAIDs at least once per week for six months or longer was reported in 301 cases (20.9 percent) and 345 controls (24.3 percent) with a 20 percent lower risk of breast cancer for ever use vs. nonusers. "The inverse association was most pronounced among frequent users [7 or more tablets per week, 28 percent lower risk]. The results for ibuprofen, which was used by fewer women on a regular basis, were generally weaker [22 percent lower risk for less than three times per week vs. 8 percent lower risk for three times or more per week]. Use of acetaminophen, an analgesic that does not inhibit prostaglandin synthesis, was not associated with a reduction in the incidence of breast cancer. The reduction in risk with aspirin use was seen among those with hormone receptor-positive tumors [26 percent lower risk] but not for women with hormone receptor-negative tumors," the authors write.

"Our data, supported by other epidemiologic and laboratory evidence, bolster the case for the use of aspirin and NSAIDs as chemopreventive agents against breast cancer, particularly among postmenopausal women. The mechanisms are probably distinct from those that are protective against gastrointestinal tract cancers. There are many attractive features to such a chemopreventive agent, including its ease of use and association with reducing risk of other health outcomes. The potential benefits need to be balanced against potential harmful effects of long-term aspirin use such as peptic ulcer disease and gastrointestinal bleeding," the researchers conclude.

Editor's Note: This work was supported in part by grants from the National Cancer Institute and the National Institute of Environmental Health Sciences.

Editorial: Aspirin and Breast Cancer Prevention — The Estrogen Connection

In an accompanying editorial, Raymond N. DuBois, M.D., Ph.D., of the Vanderbilt University Medical Center, Nashville, Tenn., writes that the observation that receptor-positive tumors are more responsive to aspirin is consistent with previous findings. "This association needs to be confirmed before clinicians can make any definite recommendations to patients at risk for breast cancer. However, it does appear that there is emerging evidence supporting a protective effect of aspirin in estrogen receptor-positive and progesterone receptor-positive breast cancers.

"Despite the longstanding and ubiquitous nature of aspirin use, researchers are still exploring the clinical outcome of aspirin treatment in humans. Unfortunately, all the answers are not available and current information is insufficient to make any definite recommendations to patients. Women who take daily aspirin for cardiovascular indications may gain additional benefits with regard to reduction in their risk for certain cancers, such as hormone receptor-positive breast cancer. However, the optimal aspirin dose or regimen required to achieve a maximal reduction in cancer risk remains unknown," Dr. DuBois concludes.

 

Aspirin reduces overall cancer and mortality rates

Last Updated: 2007-04-17 11:04:27 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The regular use of aspirin, but not other nonsteroidal anti-inflammatory drugs (NSAIDs), is associated with a reduced incidence of cancer and cancer-related death, particularly among former smokers and those who never smoked.

NSAIDs include commonly used analgesic drugs, such as ibuprofen and naproxen, that are usually available over-the-counter.

The findings were reported Monday at the 100th annual gathering of the American Association for Cancer Research in Los Angeles by Dr. Aditya Bardia of Mayo Clinic College of Medicine, Rochester, Minnesota.

"The take-home message is that aspirin might have anti-cancer effects, but can also have adverse effects such as gastric bleeding. One should speak to his or her doctor about the risks and benefits of aspirin use," Bardia told Reuters Health.

Previous studies have looked at whether aspirin or NSAIDs prevent specific cancers, such as breast cancer, Bardia noted.

"Our study is different in the sense that it is a large...study that looked at the association between aspirin and non-aspirin use, and overall cancer incidence and mortality, in a comprehensive fashion, and also evaluated the results by smoking status," the lead researcher said.

Among 22,507 postmenopausal women in the Iowa Women's Health Study who were followed for up to 12 years, 3,487 developed cancer and 1,193 died from the disease.

Regular aspirin use, compared with no aspirin use, was associated with a 16-percent lower risk of cancer and a 13-percent lower risk of cancer death, the team reported.

The inverse association between aspirin use and the risk of cancer and cancer-related death was strongest among former smokers and those who never smoked compared with current smokers, although this fell short of statistical significance.

Aspirin use also appeared to protect patients against coronary heart disease and the overall mortality rate.

NSAID use, on the other hand, was not associated with cancer incidence or death, heart-disease death, or mortality from any cause.

This study provides "provocative evidence that regular aspirin use may play a role in preventing the most common chronic diseases in western countries, namely cancer and heart disease," Bardia said in a statement.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
Google
Web www.iconocast.com
 
 
Survey Finds Nearly Half of People With Diabetes Are Not Using Aspirin to Reduce Risk of Heart Attack and Recurrent Stroke

Findings Highlight Need For Improved Doctor/ Patient Communication About Important Preventive Therapy

July 14, 2006 — Survey results released by the American College of Preventive Medicine (ACPM) found that nearly half (48 percent) of U.S. adults 40 and over with diabetes are not utilizing aspirin therapy to reduce their risk of recurrent heart attack or stroke nor had they reported discussing such therapy with their healthcare provider.

This population is at heightened risk of cardiovascular (CV) events, and therefore potential candidates for doctor-recommended aspirin therapy based on current American Diabetes Association and U.S. Preventive Services Task Force (USPSTF) guidelines.
Heart attack and stroke are the most life-threatening consequences of diabetes, occurring more than twice as often among people with diabetes than in those who do not have the disease, and accounting for approximately 65 percent of deaths in people with diabetes.

According to the American Diabetes Association (ADA), a diagnosis of diabetes as an adult presents a similar level of coronary heart disease (CHD) risk as already having suffered a heart attack. The ADA recommends that aspirin be considered for use in the prevention of both first and recurrent CV events in patients with diabetes who have at least one additional risk factor. Additionally, the USPSTF recommends the consideration of low-dose aspirin in people whose five-year CHD risk exceeds 3 percent, a point at which the benefits of aspirin therapy are thought to outweigh the risks; the USPSTF recommendations also note that patients with diabetes appear to benefit "as much or more from aspirin as nondiabetic patients."

Despite these treatment guidelines, the ACPM survey suggests that aspirin remains underutilized in people with diabetes, an issue that may be due in part to these individuals' tendency to underestimate their risk for a heart attack or stroke.

"The survey findings suggest that insufficient numbers of Americans with diabetes are aware of the cardio-protective benefits of aspirin," commented George K. Anderson, M.D., MPH, past president of the ACPM. Although the benefits of aspirin therapy have been proven to outweigh the risks in moderate to high risk populations, it is concerning that so many people with diabetes and at least one additional risk factor — a population that would stand to benefit from aspirin use — seem unaware of this fact," said Dr. Anderson. "Clearly, health professionals and patients — especially patients with diabetes age 40 or older — need to work together more closely to improve dialogue regarding aspirin therapy as part of a risk-reduction action plan."

It's important to remember that aspirin is not appropriate for everyone, so be sure to talk to your doctor before you begin an aspirin regimen. If you are taking a prescription product for diabetes, it is especially important to talk to your doctor because aspirin can interfere with certain diabetes medications.

Survey Findings and Implications

The results were drawn from a nationally representative on-line survey of 1,299 U.S. adult consumers (647 men, 652 women) age 40 and over and 528 healthcare professionals. The survey was designed to assess barriers, beliefs and behaviors related to adoption of cardiovascular event prevention strategies, with a particular focus on aspirin use and adherence.

Of the 1,299 survey respondents, 198 (approximately 15 percent) indicated that they have diabetes. Whereas 52 percent of respondents with diabetes reported that they take aspirin on a regular or daily basis, 11 percent said they had previously used aspirin for prevention of heart attack or stroke, and 45 percent said they had never taken aspirin for this purpose. While nearly half of the diabetic respondents said they consider themselves "extremely knowledgeable" about aspirin therapy, only 25 percent of the diabetic respondents said they strongly agree with the statement, "The benefits of aspirin therapy generally outweigh the risks."

The survey findings suggest that healthcare professionals believe they are discussing the risks and benefits of aspirin therapy with their patients with diabetes more frequently than patients report having this discussion with their healthcare provider. Although the survey did not explore the underlying reasons for patient behaviors, there was a significantly smaller percentage of diabetic respondents reporting aspirin use (52 percent), as compared with those reporting implementation of lifestyle changes (86 percent) and use of prescription medication (81 percent).

"Although the survey did not quantify how often healthcare professionals recommended aspirin, or how many patients received this recommendation, the disparity in consumer and professional responses suggests that many candidates for aspirin need to understand their risk and take action by talking to their doctor about aspirin," said Dr. Anderson. "While this is true for the population as a whole, the need for improved physician/patient communication surrounding aspirin is particularly pronounced for individuals with diabetes, given the heightened level of risk and suboptimal utilization in this patient group."

Methodology

Harris Interactive® conducted the online survey October 21 through 29, 2004 among a nationwide crosssection of 1,299 U.S. adults aged 40 and over. The data were weighted to be representative of the total U.S. adult population on the basis of region, age within gender, education, household income, race/ethnicity, and propensity to be online.

Participants were grouped as increased risk using a formula that is based in part on the Framingham Risk Calculator, a simplified measurement tool that assesses an individual's risk profile based upon a series of factors, including age, gender, previous cardiovascular events, presence of risk factors such as high cholesterol, blood pressure or diabetes, obesity, and other contributors such as smoking and family history of heart disease.

The sampling error for the overall results is +/- 3 percentage points. Sampling errors for the subsamples of men is +/- 4 percentage points, women is +/- 4 percentage points, adults who are at an increased risk for heart disease is +/- 4 percentage points, increased risk men is +/- 5 percentage points, increased-risk women is +/- 7 percentage points, increased-risk women who have discussed their heart health with a healthcare professional is +/- 7 percentage points, and increased-risk adults who have not experienced a heart attack is +/- 4 percentage points. This online sample was not a probability sample.

Harris Interactive also conducted a companion survey online from October 21 through November 8, 2004, among 533 healthcare professionals, of whom 212 were primary care physicians, 210 were cardiologists, and 111 were nurses. The primary care physician and cardiologist data were weighted to be representative of their respective populations in the U.S. The nurse data are unweighted and are therefore only representative of the population of nurses surveyed. The nursing database was provided by the Preventive Cardiovascular Nurses Association (PCNA), and consisted of PCNA members. The sampling error for the physician results is +/-7 percentage points and for the nurse results it is +/- 10 percentage points. This online sample is not a probability sample.

A Note on the Results

Survey research, regardless of how it is conducted or whom it surveys, must often be interpreted with caution when analyzing the results. The following caveats apply to this survey. First, many of the questions asked of both the consumer and healthcare professional samples were framed in such a way as to measure whether a certain activity has "ever" been done or discussed. Follow-up questions were not included to quantify the frequency with which these actions are taken. Secondly, the risk calculation used to identify consumers who are at increased risk for heart disease is based solely on information gathered as part of this survey and does not include information from any other sources such as patient medical records. Third, in some cases, questions were worded such that "heart attack" and "stroke" were combined into one item rather than being asked about separately (e.g., a response choice for one question was worded as "preventing heart attack or stroke"). Therefore, it is not possible to determine how respondents would answer for each cardiac event separately.

Editor's note: The survey, which was conducted by Harris Interactive® in collaboration with the ACPM, was supported by an unrestricted educational grant from Bayer HealthCare, the makers of Bayer Aspirin.

 

Moderate Decreased Cancer Risk And Long-Term Use Of Adult-Strength Aspirin Linked


A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

The Women's Health Study trial recently reported that long-term use of low-dose aspirin (about 100mg every other day) does not reduce a woman's cancer risk, but it did not examine whether high doses of aspirin have an effect on cancer risk.

Eric Jacobs, Ph.D., of the American Cancer Society in Atlanta, and colleagues looked for associations between long-term daily aspirin use (at least 325mg/day) and cancer incidence in a group of nearly 70,000 men and 76,000 women. Aspirin use was determined by a questionnaire.

During the 12 year follow-up, nearly 18,000 men and women in the study were diagnosed with cancer. The researchers found that daily use of adult-strength aspirin for at least five years was associated with an approximately 15 percent relative reduction in overall cancer risk, though the decrease was not statistically significant in women. Additionally, aspirin use was associated with a 20 percent reduced risk of prostate cancer and a 30 percent reduced risk of colorectal cancer in men and women, compared to people who didn't take aspirin. There was no effect on risk in other cancers examined - lung cancer, bladder cancer, melanoma, leukemia, non-Hodgkins lymphoma, pancreatic cancer, and kidney cancer. Aspirin use for less than five years was not associated with decreased cancer risk.

"Our results do not have immediate clinical implications. Confirmation from randomized trials is necessary before a reduction in cancer risk could be considered a benefit of using adult-strength aspirin. Our results indicate that a randomized trial examining the effect of aspirin on cancer incidence would need to be both large and long term, probably lasting a minimum of 10 years. More evidence is needed before any such trial can be justified," the authors write.

In an accompanying editorial, Maria Elena Martinez, Ph.D., of the Arizona Cancer Center in Tucson, and E. Robert Greenberg, M.D., of the Fred Hutchinson Cancer Center in Seattle, write that, for the average person, the side effects of daily long-term aspirin use, such as intestinal bleeding or stroke, might outweigh the its benefits of cancer prevention. "However, if aspirin were shown to truly prevent a multitude of common cancers, there might be clinical situations in which daily adult-strength aspirin would be indicated," the authors write.

###

Contact:

Article: Eric Jacobs, American Cancer Society

Editorial: Maria Elena Martinez, Arizona Cancer Center

Citation:

Article: Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence. J Natl Cancer Inst 2007; 99: 608-615

Editorial: Martinez ME, Greenberg ER. More Aspirin for Less Cancer? J Natl Cancer Inst 2007; 99: 582-583

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Contact: Liz Savage
Journal of the National Cancer Institute
 


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Disclaimer

Negación

Home

Contact Iconocast

Keywords: